Skip to main content

Advertisement

SpringerLink
Log in

Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

Acromegaly is associated with an enhanced mortality, with cardiovascular and respiratory complications representing not only the most frequent comorbidities but also two of the main causes of deaths, whereas a minor role is played by metabolic complications, and particularly diabetes mellitus. The most prevalent cardiovascular complications of acromegaly include a cardiomyopathy, characterized by cardiac hypertrophy and diastolic and systolic dysfunction together with arterial hypertension, cardiac rhythm disorders and valve diseases, as well as vascular endothelial dysfunction. Biochemical control of acromegaly significantly improves cardiovascular disease, albeit completely recovering to normal mainly in young patients with short disease duration. Respiratory complications, represented mainly by sleep-breathing disorders, particularly sleep apnea, and respiratory insufficiency, frequently occur at the early stage of the disease and, although their severity decreases with disease control, this improvement does not often change the indication for a specific therapy directed to improve respiratory function. Metabolic complications, including glucose and lipid disorders, are variably reported in acromegaly. Treatments of acromegaly may influence glucose metabolism, and the presence of diabetes mellitus in acromegaly may affect the choice of treatments, so that glucose homeostasis is worth being monitored during the entire course of the disease. Early diagnosis and prompt treatment of acromegaly, aimed at obtaining a strict control of hormone excess, are the best strategy to limit the development or reverse the complications and prevent the premature mortality.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleimberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94:1509–1517

    Article  CAS  PubMed  Google Scholar 

  2. Clayton RN (2003) Cardiovascular function in acromegaly. Endocr Rev 24:272–274

    Article  CAS  PubMed  Google Scholar 

  3. Melmed S (2006) Medical progress: acromegaly. New Engl J Med 355:2558–2573

    Article  CAS  PubMed  Google Scholar 

  4. Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis and management. Endocr Rev 25:102–152

    Article  CAS  PubMed  Google Scholar 

  5. Giustina A, Boni E, Romanelli G, Grassi V, Giustina G (1995) Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide. Am J Cardiol 75:1042–1047

    Article  CAS  PubMed  Google Scholar 

  6. Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89(2):667–674

    Article  CAS  PubMed  Google Scholar 

  7. Ritvonen E, Löyttyniemi E, Jaatinen P, Ebeling T, Moilanen L, Nuutila P, Kauppinen-Mäkelin R, Schalin-Jäntti C (2015) Mortality in acromegaly: a 20-year follow-up study. Endocr Relat Cancer 23(6):469–480

    Article  PubMed  Google Scholar 

  8. Mercado M, Gonzalez B, Vargas G, Ramirez C, de los Monteros AL, Sosa E, Jervis P, Roldan P, Mendoza V, López-Félix B, Guinto G (2014) Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J Clin Endocrinol Metab 99(12):4438–4446

    Article  CAS  PubMed  Google Scholar 

  9. Kahaly G, Olshausen KV, Mohr-Kahaly S, Erbel R, Boor S, Beyer J, Meyer J (1992) Arrhythmia profile in acromegaly. Eur Heart J 13(1):51–56

    Article  CAS  PubMed  Google Scholar 

  10. Colao A, Spinelli L, Marzullo P, Pivonello R, Petretta M, Di Somma C, Vitale G, Bonaduce D, Lombardi, G (2003) High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. J Clin Endocrinol Metab 88(7):3196–3201

    Article  CAS  PubMed  Google Scholar 

  11. Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R (1980) Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol 12:71–79

    Article  CAS  Google Scholar 

  12. Nabarro JDN (1987) Acromegaly. Clin Endocrinol 26:481–512

    Article  CAS  Google Scholar 

  13. Bengtsson BA, Eden S, Ernest I, Oden A, Sjögren B (1988) Epidemiology and long-term survival in acromegaly: a study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 223:327–335

    Article  CAS  PubMed  Google Scholar 

  14. Giordano C, Ciresi A, Amato MC et al (2012) Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study. Pituitary 15(4):539–551

    Article  CAS  PubMed  Google Scholar 

  15. Kreze A, Kreze-Spirova E, Mikulecky M (2001) Risk factors for glucose intolerance in active acromegaly. Braz J Med Biol Res 34:1429–1433

    Article  CAS  PubMed  Google Scholar 

  16. Ciresi A, Amato MC, Pivonello R et al (2013) The metabolic profile in active acromegaly is gender-specific. J Clin Endocrinol Metab 98(1):E51–E59

    Article  CAS  PubMed  Google Scholar 

  17. Colao A, Pivonello R, Galderisi M, Cappabianca P, Auriemma RS, Galdiero M, Cavallo LM, Esposito F, Lombardi G (2008) Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J Clin Endocrinol Metab 93(7):2639–2646

    Article  CAS  PubMed  Google Scholar 

  18. Colao A, Marzullo P, Cuocolo A, Spinelli L, Pivonello R, Bonaduce D, Salvatore M, Lombardi G (2003) Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin Endocrinol 58:169–176

    Article  CAS  Google Scholar 

  19. Espinosa-de-los-Monteros AL, González B, Vargas G et al (2011) Clinical and biochemical characteristics of acromegalic patients with different abnormalities in glucose metabolism. Pituitary 14:231–235

    Article  CAS  PubMed  Google Scholar 

  20. Portocarrero-Ortiz LA, Vergara-Lopez A, Vidrio-Velazquez M et al (2016) The Mexican Acromegaly Registry: clinical and biochemical characteristics at diagnosis and therapeutic outcomes. J Clin Endocrinol Metab 101(11):3997–4004

    Article  CAS  PubMed  Google Scholar 

  21. Kasayama S, Otsuki M, Takagi M et al (2000) Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol 52:549–555

    Article  CAS  Google Scholar 

  22. Fieffe S, Morange I, Petrossians P et al (2011) Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. Eur J Endocrinol 164(6):877–884

    Article  CAS  PubMed  Google Scholar 

  23. Colao A, Marzullo P, Di Somma C, Lombardi, G (2001) Growth hormone and the heart. Clin Endocrinol 54:137–154

    Article  CAS  Google Scholar 

  24. Isgaard J, Tivesten A, Friberg P, Bengtsson BA (1999) The role of the GH/IGF-I axis for the cardiac function and structure. Horm Metab Res 31:50–54

    Article  CAS  PubMed  Google Scholar 

  25. Isgaard J, Nilsson A, Vickman K, Isaksson, OGP (1989) Growth hormone regulates the level of insulin-like growth factor-ImRNAin rats skeletal muscle. J Endocrinol 120:107–112

    Article  CAS  PubMed  Google Scholar 

  26. Delafontaine P (1995) Insulin-like growth factor I and its binding proteins in the cardiovascular system. Cardiovasc Res 30:825–834

    Article  CAS  PubMed  Google Scholar 

  27. Han VK, D’Ercole AJ, Lund PK (1987) Cellular localization of somatomedin (insulin-like growth factor) messenger RNA in the human fetus. Science 236:193–197

    Article  CAS  PubMed  Google Scholar 

  28. Cittadini A, Stromer H, Katz SE, Clark R, Moses AC, Morgan JP, Douglas PS (1996) Differential cardiac effects of growth hormone and insulin-like growth factor-I in the rat. A combined in vivo and in vitro evaluation. Circulation 93:800–809

    Article  CAS  PubMed  Google Scholar 

  29. Lu C, Schwartzbauer G, Sperling MA, Devaskar SU, Thamotharan S, Robbins PD, McTiernan CF, Liu JL, Jiang J, Frank SJ, Menon RK (2001) Demonstration of direct effects of growth hormone on neonatal cardiomyocytes. J Biol Chem 276:22892–22900

    Article  CAS  PubMed  Google Scholar 

  30. Vetter U, Kupferschmid C, Lang D, Pents S (1988) Insulin-like growth factors and insulin increase the contractility of neonatal rat cardiocytes in vitro. Basic Res Cardiol 83:647–654

    Article  CAS  PubMed  Google Scholar 

  31. Brüel A, Christoffersen TE, Nyengaard JR (2007) Growth hormone increases the proliferation of existing cardiac myocytes and the total number of cardiac myocytes in the rat heart. Cardiovasc Res 76(3):400–408

    Article  PubMed  CAS  Google Scholar 

  32. Thuesen L, Christensen SE, Weeke J, Orskov H, Henningsen P (1988) A hyperkinetic heart in uncomplicated active acromegaly. Explanation of hypertension in acromegalic patients? Acta Med Scand 223:337–343

    Article  CAS  PubMed  Google Scholar 

  33. Vitale G, Pivonello R, Galderisi M, D’Errico A, Spinelli L, Lupoli G, Lombardi G, Colao A (2001) Cardiovascular complications in acromegaly: methods of assessment. Pituitary 4(4):251–257

    Article  CAS  PubMed  Google Scholar 

  34. Lombardi G, Colao A, Marzullo P, Ferone D, Longobardi S, Esposito V, Merola B (1997) Is growth hormone bad for your heart? Cardiovascular impact of GH deficiency and of acromegaly. J Endocrinol 155:S33

    CAS  PubMed  Google Scholar 

  35. Courville C, Mason VR (1938) The heart in acromegaly. Arch Int Med 61:704

    Article  Google Scholar 

  36. Hejtmancik MR, Bradfield JY, Herrmann GR (1951) Acromegaly and the heart: a clinical and pathologic study. Ann Intern Med 34:1445

    Article  CAS  PubMed  Google Scholar 

  37. Lie JT, Grossman SJ (1980) Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients. Am Heart J 100:41

    Article  CAS  PubMed  Google Scholar 

  38. Hayward RP, Emanuel RW, Nabarro, J.D.N. (1987) Acromegalic heart disease: influence of treatment of the acromegaly on the heart. Q J Med 62:41

    CAS  PubMed  Google Scholar 

  39. Bogazzi F, Lombardi M, Strata E, Aquaro G, Di Bello V, Cosci C, Sardella C, Talini E, Martino E (2008) High prevalence of cardiac hypertophy without detectable signs of fibrosis in patients with untreated active acromegaly: an in vivo study using magnetic resonance imaging. Clin Endocrinol 68(3):361–368

    Article  Google Scholar 

  40. dos Santos Silva CM, Gottlieb I, Volschan I, Kasuki L, Warszawski L, Balarini Lima GA, Xavier SS, Pedrosa RC, Neto LV, Gadelha MR (2015) Low frequency of cardiomyopathy using cardiac magnetic resonance imaging in an acromegaly contemporary cohort. J Clin Endocrinol Metab 100(12):4447–4455

    Article  PubMed  CAS  Google Scholar 

  41. Colao A, Baldelli R, Marzullo P, Ferretti E, Ferone D, Gargiulo P, Petretta M, Tamburrano G, Lombardi G, Liuzzi A (2000) Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 85:193–199

    CAS  PubMed  Google Scholar 

  42. Bondanelli M, Ambrosio MR, degli Uberti EC (2001) Pathogenesis and prevalence of hypertension in acromegaly. Pituitary 4(4):239–249

    Article  CAS  PubMed  Google Scholar 

  43. Feld S, Hirschgerg R (1996) Growth Hormone, the insulin-like growth factor system, and the kidney. J Clin Endocrinol Metab 5:423–480

    Google Scholar 

  44. Hansen TK, Møller J, Thomsen K, Frandsen E, Dall R, Jørgensen JO, Christiansen JS (2001) Effects of growth hormone on renal tubular handling of sodium in healthy humans. Am J Physiol Endocrinol Metab 281(6):E1326–E1332

    CAS  PubMed  Google Scholar 

  45. Rabkin E, Aikawa M, Stone JR, Fukumoto Y, Libby P, Schoen FJ (2001) Activated myofibroblasts express catabolic enzymes and mediate matrix re- modeling in myxomatous heart valves. Circulation 104:2525–2253

    Article  CAS  PubMed  Google Scholar 

  46. Feelders RA, Savelkoul HF, de Herder WW, Hooijkaas H, Lamberts SW (2002) The cytokine network in acromegaly before and after pituitary surgery: growth hormone excess is associated with a reversible shift to the T-helper 1 cytokine response. Program of the 84th Annual Meeting of The Endocrine Society, San Francisco, CA, p 76 (Abstract OR8-5)

  47. Pereira AM, van Thiel SW, Lindner JR, Roelfsema F, van der Wall EE, Morreau H, Smit JW, Romijn JA, Bax JJ (2004) Increased prevalence of regurgitant valvular heart disease in acromegaly. J Clin Endocrinol Metab 89:71–75

    Article  CAS  PubMed  Google Scholar 

  48. van der Klaauw AA, Bax JJ, Roelfsema F, Bleeker GB, Holman ER, Corssmit EP, van der Wall EE, Smit JW, Romijn JA, Pereira AM (2006) Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation. Growth Horm IGF Res 16:101–107

    Article  PubMed  Google Scholar 

  49. Colao A, Grasso LF (2011) Aortic root ectasia in patients with acromegaly: an emerging complication. Clin Endocrinol 75(4):420–421

    Article  Google Scholar 

  50. Casini AF, Neto LV, Fontes R, França RF, Xavier SS, Gadelha MR (2011) Aortic root ectasia in patients with acromegaly: experience at a single center. Clin Endocrinol 75:495–500

    Article  Google Scholar 

  51. van der Klaauw AA, Bax JJ, Smit JW, Holman ER, Delgado V, Bleeker GB, Biermasz NR, Roelfsema, .F, Romijn JA, Pereira AM (2008) Increased aortic root diameters in patients with acromegaly. Eur J Endocrinol 159:97–103

    Article  PubMed  CAS  Google Scholar 

  52. Vitale G, Pivonello R, Lombardi G, Colao A (2004) Cardiac abnormalities in acromegaly. Pathophysiology and implications for management. Treat Endocrinol 3(5):309–318

    Article  PubMed  Google Scholar 

  53. Warszawski L, Kasuki L, Sá R, Dos Santos Silva CM, Volschan I, Gottlieb I, Pedrosa RC, Gadelha MR (2016) Low frequency of cardiac arrhythmias and lack of structural heart disease in medically-naïve acromegaly patients: a prospective study at baseline and after 1 year of somatostatin analogs treatment. Pituitary 19(6):582–589

    Article  CAS  PubMed  Google Scholar 

  54. Kırış A, Erem C, Turan OE, Civan N, Kırış G, Nuhoğlu I, Ilter A, Ersöz HO, Kutlu M (2013) Left ventricular synchronicity is impaired in patients with active acromegaly. Endocr 44:200–206

    Article  CAS  Google Scholar 

  55. Colao A, Pivonello R, Grasso LF, Auriemma RS, Galdiero M, Savastano S, Lombardi G (2011) Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study. Eur J Endocrinol 165(5):713–721

    Article  CAS  PubMed  Google Scholar 

  56. Jayasena C, Comninos A, Clarke H, Donaldson M, Meeran K, Dhillo W (2011) The effects of long term GH and IGF-I exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly. Clin Endocrinol 75:220–225

    Article  CAS  Google Scholar 

  57. Andersson IJ, Johansson ME, Wickman A, Bohlooly-Y M, Klintland N, Caidahl K, Gustafsson M, Borén J, Gan LM, Bergström G (2006) Endothelial dysfunction in growth hormone transgenic mice. Clin Sci 110(2):217–225

    Article  CAS  PubMed  Google Scholar 

  58. Anagnostis P, Efstathiadou ZA, Gougoura S, Polyzos SA, Karathanasi E, Dritsa P, Kita M, Koukoulis GN (2013) Oxidative stress and reduced antioxidative status, along with endothelial dysfunction in acromegaly. Horm Metab Res 45(4):314–318

    CAS  PubMed  Google Scholar 

  59. Ronconi V, Giacchetti G, Mariniello B, Camilletti A, Mantero F, Boscaro M, Vignini A, Mazzanti L (2005) Reduced nitric oxide levels in acromegaly: cardiovascular implications. Blood Press 14(4):227–232

    Article  CAS  PubMed  Google Scholar 

  60. Kirilov G, Zacharieva S, Alexandrov AS, Lozanov V, Mitev V (2009) Increased plasma endothelin level as an endothelial marker of cardiovascular risk in patients with active acromegaly: a comparison with plasma homocysteine. Methods Find Exp Clin Pharmacol 31(7):457–461

    Article  CAS  PubMed  Google Scholar 

  61. Baykan M, Erem C, Gedikli O, Hacihasanoglu A, Erdogan T, Kocak M, Kaplan S, Korkmaz L, Celik S (2009) Impairment in flow-mediated vasodilatation of the brachial artery in acromegaly. Med Princ Pract 18(3):228–232

    Article  PubMed  Google Scholar 

  62. Paisley AN, Izzard AS, Gemmell I, Cruickshank K, Trainer PJ, Heagerty AM (2009) Small vessel remodeling and impaired endothelial-dependent dilatation in subcutaneous resistance arteries from patients with acromegaly. J Clin Endocrinol Metab 94(4):1111–1117

    Article  CAS  PubMed  Google Scholar 

  63. Topaloglu O, Sayki Arslan M, Turak O, Ginis Z, Sahin M, Cebeci M, Ucan B, Cakir E, Karbek B, Ozbek M, Cakal E, Delibasi T (2014) Three noninvasive methods in the evaluation of subclinical cardiovascular disease in patients with acromegaly: epicardial fat thickness, aortic stiffness and serum cell adhesion molecules. Clin Endocrinol 80(5): 726–734

    Article  CAS  Google Scholar 

  64. Schiavon F, Maffei P, Martini C, De Carlo E, Fais C, Todesco S, Sicolo N (1999) Morphologic study of microcirculation in acromegaly by capillaroscopy. J Clin Endocrinol Metab 84:3151–3155

    CAS  PubMed  Google Scholar 

  65. Brevetti G, Marzullo P, Silvestro A, Pivonello R, Oliva G, di Somma C, Lombardi G, Colao A (2002) Early vascular alterations in acromegaly. J Clin Endocrinol Metab 87:3174–3179

    Article  CAS  PubMed  Google Scholar 

  66. Colao A, Spiezia S, Cerbone G, Pivonello R, Marzullo P, Ferone D, Di Somma C, Assanti AP, Lombardi G (2001) Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly. Clin Endocrinol 54:515–524

    Article  CAS  Google Scholar 

  67. Kartal I, Oflaz H, Pamukçu B, Meriç M, Aral F, Ozbey N, Alagöl F (2010) Investigation of early atherosclerotic changes in acromegalic patients. Int J Clin Pract 64:39–44

    Article  CAS  PubMed  Google Scholar 

  68. Paisley AN, Banerjee M, Rezai M, Schofield RE, Balakrishnannair S, Herbert A, Lawrance JA, Trainer PJ, Cruickshank JK (2011) Changes in arterial stiffness but not carotid intimal thickness in acromegaly. J Clin Endocrinol Metab 96:1486–1492

    Article  CAS  PubMed  Google Scholar 

  69. Bogazzi F, Battolla L, Spinelli C, Rossi G, Gavioli S, Di Bello V, Cosci C, Sardella C, Volterrani D, Talini E, Pepe P, Falaschi F, Mariani G, Martino, E (2007) Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study. J Clin Endocrinol Metab 92:4271–4277

    Article  CAS  PubMed  Google Scholar 

  70. Akutsu H, Kreutzer J, Wasmeier G, Ropers D, Rost C, Möhlig M, Wallaschofski H, Buchfelder M, Schöfl C (2010) Acromegaly per se does not increase the risk for coronary artery disease. Eur J Endocrinol 162:879–886

    Article  CAS  PubMed  Google Scholar 

  71. Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Della Morte AM, Pivonello R, Salvatore M, Lombardi G (2001) Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor levels on cardiac performance. J Clin Endocrinol Metab 86:1551–1557

    CAS  PubMed  Google Scholar 

  72. Akgul E, Tokgozoglu SL, Erbas T, Kabakci G, Aytemir K, Haznedaroglu I, Oto A, Kes SS (2010) Evaluation of the impact of treatment on endothelial function and cardiac performance in acromegaly. Echocardiography 27(8):990–996

    Article  PubMed  Google Scholar 

  73. Sakai H, Tsuchiya K, Nakayama C, Iwashima F, Izumiyama H, Doi M, Yoshimoto T, Tsujino M, Yamada S, Hirata Y (2008) Improvement of endothelial dysfunction in acromegaly after transsphenoidal surgery. Endocr J 55(5):853–859

    Article  PubMed  Google Scholar 

  74. Colao A, Auriemma RS, Galdiero M, Lombardi G, Pivonello R (2009) Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocrinol Metab 94(10):3746–3756

    Article  CAS  PubMed  Google Scholar 

  75. Annamalai AK, Webb A, Kandasamy N, Elkhawad M, Moir S, Khan F, Maki-Petaja K, Gayton EL, Strey CH, O’Toole S, Ariyaratnam S, Halsall DJ, Chaudhry AN, Berman L, Scoffings DJ, Antoun NM, Dutka DP, Wilkinson IB, Shneerson JM, Pickard JD, Simpson HL, Gurnell M (2013) A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. J Clin Endocrinol Metab 98(3):1040–1050

    Article  CAS  PubMed  Google Scholar 

  76. Colao A, Marzullo P, Ferone D, Spinelli L, Cuocolo A, Bonaduce D, Salvatore M, Boerlin V, Lancranjan I, Lombardi G (2000) Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab 86:3132–3140

    Google Scholar 

  77. Giustina A, Casanueva FF, Cavagnini F, Chanson P, Clemmons D, Frohman LA, Gaillard R, Ho K, Jaquet P, Kleinberg DL, Lamberts SW, Lombardi G, Sheppard M, Strasburger CJ, Vance ML, Wass JA, Melmed S; The Pituitary Society and the European Neuroendocrine Association (2003) Diagnosis and treatment of acromegaly complications. J Endocrinol Invest 26:1242–1247

    Article  CAS  PubMed  Google Scholar 

  78. Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Florimonte L, Salvatore M, Lombardi G (1999) Effects of one-year treatment with octreotide on cardiac performance in patients with acromegaly. J Clin Endocrinol Metab 84:17–23

    Article  CAS  PubMed  Google Scholar 

  79. Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G (2006) Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 154(3):467–477

    Article  CAS  PubMed  Google Scholar 

  80. Auriemma RS, Pivonello R, De Martino MC, Cudemo G, Grasso LF, Galdiero M, Perone Y, Colao, A (2012) Treatment with GH receptor antagonist in acromegaly: effect on cardiac arrhythmias. Eur J Endocrinol 168(1):15–22

    Article  PubMed  CAS  Google Scholar 

  81. De Martino MC, Auriemma RS, Brevetti G, Vitale G, Schiano V, Galdiero M, Grasso L, Lombardi G, Colao A, Pivonello R (2010) The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues. J Endocrinol Invest 33(9):663–670

    Article  PubMed  Google Scholar 

  82. Pivonello R, Galderisi M, Auriemma RS, De Martino MC, Galdiero M, Ciccarelli A, D’Errico A, Kourides I, Burman P, Lombardi G, Colao, A (2007) Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. J Clin Encocrinol Metab 92(2):476–482

    Article  CAS  Google Scholar 

  83. Auriemma RS, Grasso LF, Galdiero M, Galderisi M, Pivonello C, Simeoli C, De Martino MC, Ferrigno R, Negri M, de Angelis C, Pivonello R, Colao A (2016) Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. Endocrine (Epub ahead of print)

  84. Harrison BD, Millhouse KA, Harrington M, Nabarro JD (1978) Lung function in acromegaly. Q J Med 47:517–532

    CAS  PubMed  Google Scholar 

  85. Evans CC, Hipkin LJ, Murray GM (1977) Pulmonary function in acromegaly. Thorax 22:322–327

    Article  Google Scholar 

  86. Trotman-Dickenson B, Weetman AP, Hughes JM (1991) Upper airflow obstruction and pulmonary function in acromegaly: relationship to disease activity. Q J Med 79:527–538

    CAS  PubMed  Google Scholar 

  87. Luboshitzky R, Barzilai D (1980) Hypoxemia and pulmonary function in acromegaly. Am Rev Respir Dis 121:471–475

    Article  CAS  PubMed  Google Scholar 

  88. Lobie PE, Garcia-Aragon J, Wang BS, Baumback WR, Waters MJ (1992) Cellular localization of the growth hormone binding protein in the rat. Endocrinology 130:3057–3065

    CAS  PubMed  Google Scholar 

  89. Zogopoulos G, Figueiredo R, Jenab A, Ali Z, Lefebvre Y, Goodyer CG (1996) Expression of exon 3-retaining and -deleted human growth hormone receptor messenger ribonucleic acid isoforms during development. J Clin Endocrinol Metab 81:775–782

    CAS  PubMed  Google Scholar 

  90. Hill DJ, Riley SC, Bassett NS, Waters MJ (1992) Localization of the growth hormone receptor, identified by immunocytochemistry, in second trimester human fetal tissues and in placenta throughout gestation. J Clin Endocrinol Metab 75:646–650

    CAS  PubMed  Google Scholar 

  91. Grunstein RR, Ho KY, Sullivan CE (1991) Sleep apnea in acromegaly. Ann Intern Med 115:527–532

    Article  CAS  PubMed  Google Scholar 

  92. Rom WN, Basset P, Fells GA, Nukiwa T, Trapnell BC, Crystal RG (1988) Alveolar macrophages release an insulin-like growth factor I-type molecule. J Clin Invest 82:1685–1693

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Camilo GB, Carvalho AR, Machado DC, Mogami R, Kasuki L, Gadelha MR, Melo PL, Lopes AJ (2015) Correlations between forced oscillation technique parameters and pulmonary densitovolumetry values in patients with acromegaly. Braz J Med Biol Res 48(10):877–885

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Garcia-Rio F, Pino JM, Diez JJ, Ruiz A, Villasante C, Villamor J (2001) Reduction of lung distensibility in acromegaly after suppression of growth hormone hypersecretion. Am J Respir Crit Care Med 164:852–857

    Article  CAS  PubMed  Google Scholar 

  95. Noveral JP, Bhala A, Hintz RL, Grunstein MM, Cohen P (1994) Insulin-like growth factor axis in airway smooth muscle cells. Am J Physiol 267:L761–L765

    CAS  PubMed  Google Scholar 

  96. Rich CB, Ewton DZ, Martin BM, Florini JR, Bashir M, Rosenbloom J, Foster JA (1992) IGF-I regulation of elastogenesis: comparison of aortic and lung cells. Am J Physiol 263:L276–L282

    CAS  PubMed  Google Scholar 

  97. Weiss V, Sonka K, Pretl M, Dostalova S, Klozar J, Rambousek P, Marek J, Haas T (2000) Prevalence of the sleep apnea syndrome in acromegaly population. J Endocrinol Invest 23:515–519

    Article  CAS  PubMed  Google Scholar 

  98. Dostalova S, Sonka K, Smahel Z, Weiss V, Marek J, Horinek D (2001) Craniofacial abnormalities and their relevance for sleep apnea syndrome aetiopathogenesis in acromegaly. Eur J Endocrinol 144:491–497

    Article  CAS  PubMed  Google Scholar 

  99. Ip, MSM, Tan KCB, Peh WCG, Lam KSL (2001) Effect of Sandostatin LAR on sleep apnoea in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity. Clin Endocrinol 55:477–483

    Article  CAS  Google Scholar 

  100. Chemla D, Attal P, Maione L, Veyer AS, Mroue G, Baud D, Salenave S, Kamenicky P, Bobin S, Chanson P (2014) Impact of successful treatment of acromegaly on overnight heart rate variability and sleep apnea. J Clin Endocrinol Metab 99(8):2925–2931

    Article  CAS  PubMed  Google Scholar 

  101. Isono S, Saeki N, Tanaka A, Nishino T (1999) Collapsibility of passive pharynx in patients with acromegaly. Am J Respir Crit Care Med 160:64–68

    Article  CAS  PubMed  Google Scholar 

  102. Morewood DJ, Belchetz PE, Evans CC, Whitehouse GH (1986) The extrathoracic airway in acromegaly. Clin Radiol 37:243–246

    Article  CAS  PubMed  Google Scholar 

  103. Perks WH, Horrocks PM, Cooper RA, Bradbury S, Allen A, Baldock N, Prowse K, van’t Hoff W (1980) Sleep apnoea in acromegaly. Br Med J 280:894–897

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Hart TB, Radow SK, Blackard WG, Tucker HS, Cooper KR (1985) Sleep apnea in active acromegaly. Arch Intern Med 145:865–866

    Article  CAS  PubMed  Google Scholar 

  105. Iandelli I, Gorini M, Duranti R, Bassi F, Misuri G, Pacini F, Rosi E, Scano G (1997) Respiratory muscle function and control of breathing in patients with acromegaly. Eur Respir J 10:977–982

    Article  CAS  PubMed  Google Scholar 

  106. Colao A, Spinelli L, Cuocolo A, Spiezia S, Bonaduce D, Salvatore M, Lombardi G (2002) Cardiovascular consequences of early-onset growth hormone excess. J Clin Endocrinol Metab 87:3097–3104

    Article  CAS  PubMed  Google Scholar 

  107. Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Della Morte AM, Petretta M, Salvatore M, Lombardi G (1999) Impact of patient’s age and disease duration on cardiac performance in acromegaly: A radionuclide angiography study. J Clin Endocrinol Metab 84:1518–1523

    CAS  PubMed  Google Scholar 

  108. Thomas SG, Woodhouse LJ, Pagura SM, Ezzat S (2002) Ventilation threshold as a measure of impaired physical performance in adults with growth hormone excess. Clin Endocrinol 56:351–358

    Article  CAS  Google Scholar 

  109. Pekkarinen T, Partinen M, Pelkonen R, Ivanainen M (1987) Sleep apnoea and daytime sleepiness in acromegaly: relationship to endocrinological factors. Clin Endocrinol 27:649–654

    Article  CAS  Google Scholar 

  110. Pelttari L, Polo O, Rauhala E, Vuoriluoto J, Aitasalo K, Hyyppa MT, Kronholm E, Irjala K, Viikari J (1995) Nocturnal breathing abnormalities in acromegaly after adenomectomy. Clin Endocrinol 43:175–182

    Article  CAS  Google Scholar 

  111. Rosenow F, Reuter S, Deuss U, Szelies B, Hilgers RD, Winkelmann W, Heiss WD (1996) Sleep apnoea in treated acromegaly: relative frequency and predisposing factors. Clin Endocrinol 45:563–569

    Article  CAS  Google Scholar 

  112. Chanson P, Timsit J, Benoit O, Augendre B, Moulonguet M, Guillausseau PG, Warnet A, Lubetzki J (1986) Rapid improvement of sleep apnoea of acromegaly after short term treatment with somatostatin analogue SMS 201–995. Lancet 1:1270–1271

    Article  CAS  PubMed  Google Scholar 

  113. Grunstein RR, Ho KK, Sullivan CE (1994) Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly. Ann Intern Med 121(7):478–483

    Article  CAS  PubMed  Google Scholar 

  114. Berg C, Wessendorf TE, Mortsch F, Forsting M, Teschler H, Weischer T, Mann K, Saller B, Herrmann BL (2009) Influence of disease control with pegvisomant on sleep apnoea and tongue volume in patients with active acromegaly. Eur J Endocrinol 161(6):829–835

    Article  CAS  PubMed  Google Scholar 

  115. Sze L, Schmid C, Bloch KE, Bernays R, Brändle M (2007) Effect of transsphenoidal surgery on sleep apnoea in acromegaly. Eur J Endocrinol 156(3):321–329

    Article  CAS  PubMed  Google Scholar 

  116. Barrett-Connor E, Dam TT, Stone K, Harrison SL, Redline S, Orwoll E, Osteoporotic Fractures in Men Study Group (2008) The association of testosterone levels with overall sleep quality, sleep architecture, and sleep-disordered breathing. J Clin Endocrinol Metab 93(7):2602–2609

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. Oh MM, Kim JW, Jin MH, Kim JJ, Moon du G (2012) Influence of paradoxical sleep deprivation and sleep recovery on testosterone level in rats of different ages. Asian J Androl 14:330–334

    Article  CAS  PubMed  Google Scholar 

  118. Killick R, Wang D, Hoyos CM et al (2013) The effects of testosterone on ventilatory responses in men with obstructive sleep apnoea: a randomised, placebo-controlled trial. J Sleep Res 22:331–336

    Article  PubMed  Google Scholar 

  119. Wittert G (2014) The relationship between sleep disorders and testosterone. Curr Opin Endocrinol Diabetes Obes 21(3):239–243

    Article  CAS  PubMed  Google Scholar 

  120. Akkoyunlu ME, Ilhan MM, Bayram M, Taşan E, Yakar F, Ozçelik HK, Karakose F, Kart L (2013) Does hormonal control obviate positive airway pressure therapy in acromegaly with sleep-disordered breathing? Respir Med 107(11):1803–1809

    Article  PubMed  Google Scholar 

  121. De Menis E, Giustina A, Colao A, Degli Uberti E, Ghigo E, Minuto F, Bogazzi F, Drigo R, Cattaneo A, Aimaretti G, COM.E.T.A. Italian Study Group (2011) Assessment of the awareness and management of sleep apnea syndrome in acromegaly. The COM.E.TA (Comorbidities Evaluation and Treatment in Acromegaly) Italian Study Group. J Endocrinol Invest 34(1):60–64

    Article  PubMed  Google Scholar 

  122. Attal P, Chanson P (2010) Endocrine aspects of obstructive sleep apnea. J Clin Endocrinol Metab 95(2):483–495

    Article  CAS  PubMed  Google Scholar 

  123. Davi’ MV, Dalle Carbonare L, Giustina A, Ferrari M, Frigo A, Lo Cascio V, Francia, G (2008) Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. Eur J Endocrinol 159(5):533–540

    Article  PubMed  CAS  Google Scholar 

  124. Galerneau LM, Pépin JL, Borel AL, Chabre O, Sapene M, Stach B, Girey-Rannaud J, Arnol N, Tamisier R, Caron P, Scientific council and investigators of the French national sleep apnoea registry (OSFP) (2016) Acromegaly in sleep apnoea patients: a large observational study of 755 patients. Eur Respir J 48(5):1489–1492

    Article  PubMed  Google Scholar 

  125. Melmed S, Casanueva FF, Klibanski A, Bronstein MD, Chanson P, Lamberts SW, Strasburger CJ, Wass JA, Giustina A (2013) A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 16(3):294–302

    Article  CAS  PubMed  Google Scholar 

  126. Alexopoulou O, Bex M, Kamenicky P et al (2014) Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary 17(1):81–89

    Article  CAS  PubMed  Google Scholar 

  127. Reid TJ, Post KD, Bruce JN et al (2010) Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol 72(2):203–208

    Article  Google Scholar 

  128. Arosio M, Reimondo G, Malchiodi E et al (2012) Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol 167(2):189–198

    CAS  PubMed  Google Scholar 

  129. Clemmons DR (2002) Roles of insulin-like growth factor-I and growth hormone in mediating insulin resistance in acromegaly. Pituitary 5(3):181–183

    Article  CAS  PubMed  Google Scholar 

  130. Møller N, Jørgensen JO (2009) Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 30(2):152–177

    Article  PubMed  CAS  Google Scholar 

  131. Frara S, Maffezzoni F, Mazziotti G, Giustina A (2016) Current and emerging aspects of diabetes mellitus in acromegaly. Trends Endocrinol Metab 27(7):470–483

    Article  CAS  PubMed  Google Scholar 

  132. Dal J, List EO, Jørgensen JO, Berryman DE (2016) Glucose and fat metabolism in acromegaly: from mice models to patient care. Neuroendocrinology 103(1):96–105

    Article  CAS  PubMed  Google Scholar 

  133. Kasayama S, Otsuki M, Takagi M et al (2000) Impaired-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol 52:549–555

    Article  CAS  Google Scholar 

  134. Drogan D, Schulze MB, Boeing H, Pischon T (2016) Insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in relation to the risk of type 2 diabetes mellitus: results from the epic-potsdam study. Am J Epidemiol 183(6):553–560

    Article  PubMed  Google Scholar 

  135. Fieffe S, Morange I, Petrossians P et al (2011) Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. Eur J Endocrinol 164:877–884

    Article  CAS  PubMed  Google Scholar 

  136. Dreval AV, Trigolosova IV, Misnikova IV et al (2014) Prevalence of diabetes mellitus in patients with acromegaly. Endocr Connect 3:93–98

    Article  CAS  PubMed  Google Scholar 

  137. Colao A, Auriemma RS, Galdiero M et al (2009 Feb) Impact of somatostatin analogues versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study. J Clin Endocrinol Metab 94(2):528–537

    Article  CAS  PubMed  Google Scholar 

  138. Grasso LF, Auriemma RS, Pivonello R, Colao A (2015) Adverse events associated with somatostatin analogs in acromegaly. Expert Opin Drug Saf 14(8):1213–1226

    Article  CAS  PubMed  Google Scholar 

  139. Caron P, Morange-Ramos I, Cogne M, Jaquet P (1997) Three year follow up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 82(1):18–22

    CAS  PubMed  Google Scholar 

  140. Mazziotti G, Floriani I, Bonadonna S et al (2009) Effects of somatostatin analogues on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab 94(5):1500–1508

    Article  CAS  PubMed  Google Scholar 

  141. Jonas C, Maiter D, Alexopoulou O (2016) Evolution of glucose tolerance after treatment of acromegaly: a study in 57 patients. Horm Metab Res 48(5):299–305

    Article  CAS  PubMed  Google Scholar 

  142. Valea A, Carsote M, Ghervan C, Georgescu C (2015) Glycemic profile in patients with acromegaly treated with somatostatin analogue. J Med Life 8 Spec Issue:82–86

    PubMed  PubMed Central  Google Scholar 

  143. Pereira AM, Biermasz NR, Roelfsema F, Romijn JA (2005) Pharmacologic therapies for acromegaly: a review of their effects on glucose metabolism and insulin resistance. Treat Endocrinol 4(1):43–53

    Article  CAS  PubMed  Google Scholar 

  144. Mazziotti G, Porcelli T, Bogazzi F et al (2011 Mar) Effect of high dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. Eur J Endocrinol 164(3):341–347

    Article  CAS  PubMed  Google Scholar 

  145. Colao A, Bronstein MD, Freda P et al (2014) Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 99(3):791–799

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  146. Ho KK, Jenkins AB, Furler SM et al (1992) Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly. Clin Endocrinol 36(3):271–279

    Article  CAS  Google Scholar 

  147. Colao A (2012) Improvement of cardiac parameters in patients with acromegaly treated with medical therapies. Pituitary 15(1):50–58

    Article  PubMed  Google Scholar 

  148. Higham CE, Rowles S, Russell-Jones D et al (2009) Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly. J Clin Endocrinol Metab 94(7):2459–2463

    Article  CAS  PubMed  Google Scholar 

  149. Kinoshita Y et al (2011) Impaired glucose metabolism in Japanese patients with acromegaly is restored after successful pituitary surgery in pancreatic b-cell function is preserved. Eur J Endocrinol 164:467–473

    Article  CAS  PubMed  Google Scholar 

  150. Singh V, Brendel MD, Zacharias S et al (2007) Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets. J Clin Endocrinol Metab 92(2):673–680

    Article  CAS  PubMed  Google Scholar 

  151. Braun M (2014) The somatostatin receptor in human pancreatic β-cells. Vitam Horm 95:165–193

    Article  CAS  PubMed  Google Scholar 

  152. Lamberts SW, Uitterlinden P, Verschoor L et al (1985) Long-term treatment of acromegaly with the somatostatin analogue SMS 201–995. N Engl J Med 313(25):1576–1580

    Article  CAS  PubMed  Google Scholar 

  153. Breidert M, Pinzer T, Wildbrett J et al (1995) Long-term effect of octreotide in acromegaly on insulin resistance. Horm Metab Res 27(5):226–230

    Article  CAS  PubMed  Google Scholar 

  154. Ronchi CL, Varca V, Beck-Peccoz P et al (2006) Comparison between six-year therapy with long-acting somatostatin analogues and successful surgery in acromegaly: effects on cardiovascular risk factors. J Clin Endocrinol Metab 91(1):121–128

    Article  CAS  PubMed  Google Scholar 

  155. Steffin B, Gutt B, Bidlingmaier M et al (2006) Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly. Eur J Endocrinol 155(1):73–78

    Article  CAS  PubMed  Google Scholar 

  156. Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S (2013) Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 98(8):3446–3453

    Article  CAS  PubMed  Google Scholar 

  157. Zambre Y, Ling Z, Chen MC, Hou X et al (1999) Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5. Biochem Pharmacol 57(10):1159–1164

    Article  CAS  PubMed  Google Scholar 

  158. Chisholm C, Greenberg GR (2002) Somatostatin-28 regulates GLP-1 secretion via somatostatin receptor subtype 5 in rat intestinal cultures. Am J Physiol Endocrinol Metab 283(2):E311–E317

    Article  CAS  PubMed  Google Scholar 

  159. Gadelha MR, Bronstein MD, Brue T et al (2014) Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controller acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2(11):875–884

    Article  CAS  PubMed  Google Scholar 

  160. Grasso LF, Pivonello R, Colao A (2013) Investigational therapies for acromegaly. Expert Opin Investig Drugs 22(8):955–963

    Article  CAS  PubMed  Google Scholar 

  161. Schmid HA, Brue T, Colao A et al (2016) Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. Endocr 53(1):210–219

    Article  CAS  Google Scholar 

  162. Schreiber I, Buchfelder M, Droste M et al (2007) Treatment of acromegaly with the GH receptor antagonist Pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 156:75–82

    Article  CAS  PubMed  Google Scholar 

  163. Drake WM, Rowles SV, Roberts ME et al (2003) Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to Pegvisomant. Eur J Endocrinol 149:521–527

    Article  CAS  PubMed  Google Scholar 

  164. Barkan AL, Burman P, Clemmons DR et al (2005) Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to Pegvisomant. J Clin Endocrinol Metab 90:5684–5691

    Article  CAS  PubMed  Google Scholar 

  165. Ghigo E, Biller BM, Colao A et al (2009) Comparison of Pegvisomant and long-acting octreotide in patients with acromegaly naïve to radiation and medical therapy. J Endocrinol Invest 32:924–933

    Article  CAS  PubMed  Google Scholar 

  166. Lindberg-Larsen R, Møller N, Schmitz O et al (2007) The impact of Pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. J Clin Endocrinol Metab 92:1724–1728

    Article  CAS  PubMed  Google Scholar 

  167. Higham CE, Rowles S, Russell-Jones D et al (2009) Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly. J Clin Endocrinol Metab 94:2459–2463

    Article  CAS  PubMed  Google Scholar 

  168. Rose DR, Clemmons DR (2002) Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Horm IGF Res 12:418–424

    Article  CAS  PubMed  Google Scholar 

  169. Trainer PJ, Ezzat S, D’Souza GA et al (2009) A randomized, controlled, multicentre trial comparing Pegvisomant alone with combination therapy of Pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol 71:549–557

    Article  CAS  Google Scholar 

  170. Moller L, Norrelund H, Jessen N et al (2009) Impact of growth hormone receptor blockade on substrate metabolism during fasting in healthy subjects. J Clin Endocrinol Metab 94(11):4524–4532

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  171. Kokshoorn NE, Biermasz NR, Roelfsema F et al (2011) GH replacement therapy in elderly GH-deficient patients: a systematic review. Eur J Endocrinol 164(5):657–665

    Article  CAS  PubMed  Google Scholar 

  172. Rosario PW (2011) Frequency of acromegaly in adults with diabetes or glucose intolerance and estimated prevalence in the general population. Pituitary 14(3):217–221

    Article  CAS  PubMed  Google Scholar 

  173. Wildbrett J, Hanefeld M, Fucker K et al (1997) Anomalies of lipoprotein pattern and fibrinolysis in acromegalic patients: relation to growth hormone levels and insulin–like growth factor I. Exp Clin Endocrinol Diabetes 105:331–335

    Article  CAS  PubMed  Google Scholar 

  174. Linton MF, Yancey PG, Davies SS, Jerome WGJ, Linton EF, Vickers KC (2000–2015) The role of lipids and lipoproteins in atherosclerosis. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J, Rebar R, Singer F, Vinik A (eds) Source Endotext [Internet]. MDText.com, Inc., South Dartmouth

  175. Chaves VE, Júnior FM, Bertolini GL (2013) The metabolic effects of growth hormone in adipose tissue. Endocr 44(2):293–302

    Article  CAS  Google Scholar 

  176. Beentjes JA, van Tol A, Sluiter WJ, Dullaart RP (2000) Low plasma lecithin: cholesterol acyltransferase and lipid transfer protein activities in growth hormone deficient and acromegalic men: role in altered high density lipoproteins. Atherosclerosis 153:491–498

    Article  CAS  PubMed  Google Scholar 

  177. Delaroudis SP, Efstathiadou ZA, Koukoulis GN et al (2008) Amelioration of cardiovascular risk factors with partial biochemical control of acromegaly. Clin Endocrinol 69(2):279–284

    Article  CAS  Google Scholar 

  178. Giustina A, Ambrosio MR, Beck Peccoz P et al (2014) Use of pegvisomant in acromegaly. An Italian Society of Endocrinology guideline. J Endocrinol Invest 37(10):1017–1030

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  179. Parkinson C, Drake WM, Wieringa G et al (2002) Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly. Clin Endocrinol 56(3): 303–311

    Article  CAS  Google Scholar 

  180. Sesmilo G, Fairfield WP, Katznelson L et al (2002) Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. J Clin Endocrinol Metab 87(4):1692–1699

    Article  CAS  PubMed  Google Scholar 

  181. Berg C, Petersenn S, Lahner H et al (2010) Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. J Clin Endocrinol Metab 2010;95:3648–3656

    Article  CAS  PubMed  Google Scholar 

  182. Hodish I, Barkan A (2008) Long-term effects of Pegvisomant in patients with acromegaly. Nat Clin Pract Endocrinol Metab 4:324–332

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università Federico II di Napoli, via S. Pansini 5, 80131, Naples, Italy

    Rosario Pivonello, Renata S. Auriemma, Ludovica F. S. Grasso, Claudia Pivonello, Chiara Simeoli, Roberta Patalano, Mariano Galdiero & Annamaria Colao

Authors
  1. Rosario Pivonello
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Renata S. Auriemma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ludovica F. S. Grasso
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Claudia Pivonello
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chiara Simeoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Roberta Patalano
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mariano Galdiero
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Annamaria Colao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rosario Pivonello.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pivonello, R., Auriemma, R.S., Grasso, L.F.S. et al. Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities. Pituitary 20, 46–62 (2017). https://doi.org/10.1007/s11102-017-0797-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-017-0797-7

Keywords

Search

Navigation